BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 32609415)

  • 1. SARS-CoV-2 vaccination-A plea for fast and coordinated action.
    Beer M; Doherr M; Osterrieder K; Pfeiffer D; Trimpert J
    Zoonoses Public Health; 2020 Nov; 67(7):840. PubMed ID: 32609415
    [No Abstract]   [Full Text] [Related]  

  • 2. Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination.
    Anderson RM; Vegvari C; Truscott J; Collyer BS
    Lancet; 2020 Nov; 396(10263):1614-1616. PubMed ID: 33159850
    [No Abstract]   [Full Text] [Related]  

  • 3. COVID-19 herd immunity: where are we?
    Fontanet A; Cauchemez S
    Nat Rev Immunol; 2020 Oct; 20(10):583-584. PubMed ID: 32908300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Herd Immunity Against SARS-CoV-2 a Silver Lining?
    Vignesh R; Shankar EM; Velu V; Thyagarajan SP
    Front Immunol; 2020; 11():586781. PubMed ID: 33101320
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines: Setting Expectations Appropriately.
    Heininger U
    Pediatr Infect Dis J; 2020 Jul; 39(7):e123-e124. PubMed ID: 32427644
    [No Abstract]   [Full Text] [Related]  

  • 6. The false promise of herd immunity for COVID-19.
    Aschwanden C
    Nature; 2020 Nov; 587(7832):26-28. PubMed ID: 33087872
    [No Abstract]   [Full Text] [Related]  

  • 7. Keeping track of the SARS-CoV-2 vaccine pipeline.
    Parker EPK; Shrotri M; Kampmann B
    Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
    Coudeville L; Gomez GB; Jollivet O; Harris RC; Thommes E; Druelles S; Chit A; Chaves SS; Mahé C
    Vaccine; 2020 Nov; 38(48):7588-7595. PubMed ID: 33097312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress and Concept for COVID-19 Vaccine Development.
    Wu SC
    Biotechnol J; 2020 Jun; 15(6):e2000147. PubMed ID: 32304139
    [No Abstract]   [Full Text] [Related]  

  • 11. The race for coronavirus vaccines: a graphical guide.
    Callaway E
    Nature; 2020 Apr; 580(7805):576-577. PubMed ID: 32346146
    [No Abstract]   [Full Text] [Related]  

  • 12. Whither COVID-19 vaccines?
    DeFrancesco L
    Nat Biotechnol; 2020 Oct; 38(10):1132-1145. PubMed ID: 32989315
    [No Abstract]   [Full Text] [Related]  

  • 13. Understanding COVID-19 vaccine efficacy.
    Lipsitch M; Dean NE
    Science; 2020 Nov; 370(6518):763-765. PubMed ID: 33087460
    [No Abstract]   [Full Text] [Related]  

  • 14. All eyes on a hurdle race for a SARS-CoV-2 vaccine.
    Gaebler C; Nussenzweig MC
    Nature; 2020 Oct; 586(7830):501-502. PubMed ID: 33077943
    [No Abstract]   [Full Text] [Related]  

  • 15. Advances in skin science enable the development of a COVID-19 vaccine.
    Falo LD
    J Am Acad Dermatol; 2020 Oct; 83(4):1226-1227. PubMed ID: 32485211
    [No Abstract]   [Full Text] [Related]  

  • 16. What policy makers need to know about COVID-19 protective immunity.
    Altmann DM; Douek DC; Boyton RJ
    Lancet; 2020 May; 395(10236):1527-1529. PubMed ID: 32353328
    [No Abstract]   [Full Text] [Related]  

  • 17. Covid-19: Human challenge studies will see people purposefully infected with virus.
    Mahase E
    BMJ; 2020 Oct; 371():m4101. PubMed ID: 33093016
    [No Abstract]   [Full Text] [Related]  

  • 18. Herd immunity and COVID-19.
    Chen J; Ye L; Zhou MY; Cheng YR; Wang MW; Feng ZH
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4064-4065. PubMed ID: 32374011
    [No Abstract]   [Full Text] [Related]  

  • 19. Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?
    McPartlin SO; Morrison J; Rohrig A; Weijer C
    BMJ; 2020 Nov; 371():m4258. PubMed ID: 33168564
    [No Abstract]   [Full Text] [Related]  

  • 20. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19.
    Neumann-Böhme S; Varghese NE; Sabat I; Barros PP; Brouwer W; van Exel J; Schreyögg J; Stargardt T
    Eur J Health Econ; 2020 Sep; 21(7):977-982. PubMed ID: 32591957
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.